• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

    40.42 +0.02 (+0.05%)
    Streaming Delayed Price Updated: 9:48 AM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Roche Holding AG Basel American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
    From Genentech
    Via Business Wire
    Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
    From Genentech
    Via Business Wire
    Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
    From Genentech
    Via Business Wire
    Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
    From Genentech
    Via Business Wire
    FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
    From Genentech
    Via Business Wire
    Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
    From Genentech
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
    From Genentech
    Via Business Wire
    Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
    From Genentech
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
    From Genentech
    Via Business Wire
    Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
    From Genentech
    Via Business Wire
    Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
    From Genentech
    Via Business Wire
    Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
    From Genentech
    Via Business Wire
    Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
    From Genentech
    Via Business Wire
    Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
    From Genentech
    Via Business Wire
    Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
    From Genentech
    Via Business Wire
    Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
    From Genentech
    Via Business Wire
    Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    From Genentech
    Via Business Wire
    Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
    Via Investor Brand Network
    Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
    EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Death
    Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
    From Genentech
    Via Business Wire
    Genentech Provides Update on Phase III Verona Study
    From Genentech
    Via Business Wire
    Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
    From Genentech
    Via Business Wire
    Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
    From Genentech
    Via Business Wire
    New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
    From Genentech
    Via Business Wire
    New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
    From Genentech
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.